Minocycline hydrochloride: Difference between revisions
| Line 5: | Line 5: | ||
{{CMG}}; {{AE}} {{MM}} | {{CMG}}; {{AE}} {{MM}} | ||
==Overview== | ==Overview== | ||
''' | '''Minocycline''' ([[International Nonproprietary Name|INN]]) is a [[broad-spectrum antibiotic|broad-spectrum]] [[tetracycline antibiotics|tetracycline antibiotic]], and has a broader spectrum than the other members of the group. It is a [[bacteriostatic]] antibiotic, classified as a long-acting type. As a result of its long half-life it generally has [[blood plasma|serum]] levels 2–4 times that of the simple water-soluble tetracyclines (150 mg giving 16 times the activity levels compared with 250 mg of [[tetracycline]] at 24–48 hours). | ||
Minocycline is the most lipid-soluble of the tetracycline-class antibiotics, giving it the greatest penetration into the prostate and brain, but also the greatest amount of central nervous system (CNS)-related side effects, such as vertigo. A common side effect is diarrhea. Uncommon side effects (with prolonged therapy) include skin discolouration and autoimmune disorders that are not seen with other drugs in the class. | |||
Minocycline is a relatively poor tetracycline-class antibiotic choice for urinary pathogens sensitive to this antibiotic class, as its solubility in water and levels in the urine are less than all other tetracyclines. Minocycline is metabolized by the liver and has poor urinary excretion. | |||
Minocycline is not a naturally-occurring antibiotic, but was synthesized semi-synthetically from natural tetracycline antibiotics in 1972, and marketed under the brand name ''Minocin''.<ref>[http://www.scripps.edu/chem/baran/images/grpmtgpdf/Lin_Mar_05revised.pdf "The Tetracyclines"]. Lin, DW. March 2005.</ref> | |||
==Category== | ==Category== | ||
Revision as of 06:12, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Minocycline (INN) is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2–4 times that of the simple water-soluble tetracyclines (150 mg giving 16 times the activity levels compared with 250 mg of tetracycline at 24–48 hours).
Minocycline is the most lipid-soluble of the tetracycline-class antibiotics, giving it the greatest penetration into the prostate and brain, but also the greatest amount of central nervous system (CNS)-related side effects, such as vertigo. A common side effect is diarrhea. Uncommon side effects (with prolonged therapy) include skin discolouration and autoimmune disorders that are not seen with other drugs in the class.
Minocycline is a relatively poor tetracycline-class antibiotic choice for urinary pathogens sensitive to this antibiotic class, as its solubility in water and levels in the urine are less than all other tetracyclines. Minocycline is metabolized by the liver and has poor urinary excretion.
Minocycline is not a naturally-occurring antibiotic, but was synthesized semi-synthetically from natural tetracycline antibiotics in 1972, and marketed under the brand name Minocin.[1]
Category
US Brand Names
DYNACIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Doxycycline is primarily bacteriostatic and thought to exert its antimicrobial effect by the inhibition of protein synthesis. it acts by binding to the 30S and 50S ribosomal subunits, which impairs protein synthesis by bacteria. Doxycycline is active against a wide range of gram-positive and gram-negative organisms.[2]
References
- ↑ "The Tetracyclines". Lin, DW. March 2005.
- ↑ "Minocycline hydrochloride (DOXYCYCLINE) CAPSULE [WATSON LABORATORIES, INC.]". Retrieved 9 January 2014.